Paul K. Wotton, Ph.D., is the newest board member at Kytopen. Dr. Wotton works at Obsidian Therapeutics as the Chief Executive Officer, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most recently served as the founding President and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he served as President and Chief Executive Officer of Antares Pharma (Nasdaq:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (Nasdaq: VCEL), Veloxis Pharmaceuticals A/S (Copenhagen: VELO) and Cynata Therapeutics (ASX: CYP) as its Chairman
PAULO A. GARCIA, Ph.D.
CEO & Co-Founder
Dr. Paulo A. Garcia co-invented the Flowfect® technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.
CULLEN R BUIE, Ph.D.
Co-Founder
Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.
ANN DeWITT
Ann is a General Partner at The Engine. She serves as a Board Member for Kytopen, Biobot Analytics, Cellino, Lucy Therapeutics, Quaise, Syzygy, and Vaxess Technologies. Ann was most recently at Sanofi where she held senior roles in business development and strategic venture investment. Prior to Sanofi, she was at Flagship Pioneering. Ann started her career in R&D at 3M Company, working across fields of materials, biology and engineering. Ann holds an MBA from Harvard and a PhD in Chemical Engineering from MIT. She served on the Board of Women in the Enterprise of Science and Technology and is on the Life Science Council of Springboard Enterprises.
Adam Wieschhaus, Ph.D., CFA
Adam Wieschhaus is a Director at Northpond Ventures on the firm’s life science R&D solutions, molecular diagnostics, and environmental sciences teams. Adam is a Board Director at Encodia, Inflammatix, Isolere Bio, IsoPlexis (NASDAQ: ISO), Kytopen, Ori Biotech, Slingshot Biosciences, SpeeDx, Torus Biosystems, Ultivue, and Vestaron. Adam has experience in business and science as he holds a Ph.D. from the University of Illinois College of Medicine, a B.S. in biochemistry and molecular biology from University of Georgia, and is a CFA charterholder.